Patent · US Expired

Serpentine transmembrane antigens expressed in human cancers and uses thereof

US7166714B2 · kind B2 · utility

26Cited by
1References
6Claims
0Family size

Assignee

Inventors

Key dates

Filing dateDec 31, 2003
Grant dateJan 23, 2007
Priority date
Expiry dateAug 11, 2024

Classification

  • Technology area (CPC Y)Emerging Cross-Sectional Technologies
  • CPC primaryY10T436/143333
  • WIPO fieldBiotechnology
  • WIPO sectorChemistry

Abstract

Described is a novel family of cell surface serpentine transmembrane antigens. Two of the proteins in this family are exclusively or predominantly expressed in the prostate, as well as in prostate cancer, and thus members of this family have been termed “STEAP” (Six Transmembrane Epithelial Antigens of the Prostate). Four particular human STEAPs are described and characterized herein. The human STEAPs exhibit a high degree of structural conservation among them but show no significant structural homology to any known human proteins. The prototype member of the STEAP family, STEAP-1, appears to be a type IIIa membrane protein expressed predominantly in prostate cells in normal human tissues. Structurally, STEAP-1 is a 339 amino acid protein characterized by a molecular topology of six transmembrane domains and intracellular N- and C-termini, suggesting that it folds in a “serpentine” manner into three extracellular and two intracellular loops. STEAP-1 protein expression is maintained at high levels across various stages of prostate cancer. Moreover, STEAP-1 is highly over-expressed in certain other human cancers.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.